PROCEPT BioRobotics Corp PRCT
We are a surgical robotics company focused on advancing patient care by developing transformative solutions in urology. 10-K, Item 1
- Headquarters
- San Jose, CA
- CEO
- Larry L. Wood
- Next results
- around Feb 24, 2027
PRCT among Health care peers
Six ratios from the latest 10-K. Each corner is the share of 154 peers the company is above, not a score.
What changed
12 new risk paragraphs. 10-K filed Feb 26, 2026 against Feb 27, 2025.
Each row opens the detail with the quote and the filing. A row is a change worth reading, not a verdict.
Accounting checks
11 checks on the latest 10-K. Checks, not verdicts.
0facts worth reading about all 11 checks found nothing to note
-
Receivables +0.0% ($83.5M to $83.5M) vs revenue +37.2% ($224.5M to $308.1M), -37.2 pts apart
-
Cash from operations −$49.0M vs net income −$95.6M (FY ending Dec 31, 2025)
-
Inventory +25.9% ($56.2M to $70.7M) vs revenue +37.2% ($224.5M to $308.1M), -11.4 pts apart
8 more checks with nothing to note
-
Same auditor in both 10-Ks: PricewaterhouseCoopers LLP
-
No statement of substantial doubt about going concern
-
No 8-K item 4.02 in the last 2 years
-
No NT 10-K or NT 10-Q in the last 2 years
-
The same matters as last year: Robotic Systems Revenue Recognition
-
No sentence in the 10-K concludes that controls were not effective because of a material weakness
-
No 8-K item 2.06 in the last 2 years
-
No 8-K item 1.03 in the last 2 years
In their words
12 paragraphs in Risk Factors that were not in the 10-K filed Feb 27, 2025. Quoted as filed.
-
Item 1A · new paragraph · not in the 10-K filed Feb 27, 2025 10-K, ITEM 1A
The use of artificial intelligence in our business, including in our products and internally by our employees or business partners, may expose us to additional legal, regulatory and other risks that could adversely affect our business. We use, and may continue to expand our use of, artificial intelligence (“AI”) technologies in our…
-
Item 1A · new paragraph · not in the 10-K filed Feb 27, 2025 10-K, ITEM 1A
In addition, our employees, contractors, and other third parties with whom we do business may use AI tools, including generative AI tools provided by third parties, in the course of their work. Such use may increase the risk that confidential, proprietary, or sensitive business information is inadvertently disclosed or incorporated into…
-
Item 1A · new paragraph · not in the 10-K filed Feb 27, 2025 10-K, ITEM 1A
Foreign data protection laws, including the General Data Protection Regulation, including as implemented in the United Kingdom, or collectively or GDPR, may also apply to our processing of health-related and other personal data
-
Item 1A · new paragraph · not in the 10-K filed Feb 27, 2025 10-K, ITEM 1A
As a result of new administration and associated policy changes or shifting proposals by the U.S. government, there may be greater restrictions and economic disincentives on international trade. For example, the U.S. government has pursued a new approach to trade policy, including renegotiating or terminating certain existing bilateral…
New risk paragraphs, against peers
Latest 10-K of each, Health care companies closest in revenue
Paragraphs in Risk Factors with nothing like them in the company's 10-K the year before. A count of text, not of risk.
Financial performance
Last 4 fiscal years · 10-K XBRL
| Metric | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
| Revenue | $75.0M | $136.2M | $224.5M | $308.1M |
| Net income | −$87.2M | −$105.9M | −$91.4M | −$95.6M |
| Operating cash flow | −$80.4M | −$108.0M | −$99.2M | −$49.0M |
| Free cash flow | −$83.0M | −$133.2M | −$103.6M | −$58.3M |
Revenue, FY2020 to FY2025
Ten fiscal years, each from its own 10-K · XBRL · USD
$308.1M ▲ 37.2% in FY2025−$95.6M in FY2025−$58.3M in FY2025
Recent filings
3 filings in the last 30 days · SEC EDGAR
-
Planned saleNov 6, 2026Sharma Pooja (Officer) gave notice of a planned sale of 4,710 shares worth about $93K Form 144, approximate sale date Nov 6, 2026
-
8-KNov 4, 2026Quarterly results 8-K item 2.02
-
10-QNov 4, 2026Quarterly report (10-Q) period ended Sep 30, 2026
About the company
PROCEPT BioRobotics Corp, San Jose, CA · from the 10-K filed Feb 26, 2026
We are a surgical robotics company focused on advancing patient care by developing transformative solutions in urology. We develop, manufacture and sell the AquaBeam Robotic System and HYDROS Robotic System, which are advanced, image-guided, surgical robotic systems for use in minimally invasive urologic surgery, with an initial focus on treating benign prostatic hyperplasia, or BPH. BPH is the most common prostate disease and impacts approximately 40 million men in the United States.
- Headquarters
- San Jose, CA
- Country
- United States
- Reports in
- USD
- Listed on
- Nasdaq
- Fiscal year ends
- December 31
- Last results
- Nov 4, 2026
- Incorporated in
- DE
Email alerts
Sources
The 10-K filed Feb 26, 2026 (open at SEC), compared with the 10-K filed Feb 27, 2025. Numbers from the XBRL of the 10-Ks; filings from SEC EDGAR.
Work with it: Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/PRCT/export.csv") into a cell.